Key facts
- Notable investors include YuanBio Venture Capital, SummitView Capital, Ampersand Capital Partners, Prime Value Capital Management, Westfield BioVentures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Admera Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Admera Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Admera Health
Operator of a molecular diagnostics center intended to improve the health and well-being of the global community. The company's center offers clinical diagnostics focused on the research of personalized medicine and non-invasive cancer testing by utilizing advanced genomic technologies and bioinformatics analysis for direct delivery of personalized, medically actionable results, enabling patients, physicians, and clinical researchers to redefine disease screening, diagnosis, treatment, monitoring and management through personalized drugs.
- Sector
- Healthcare
- HQ
- South Plainfield, NJ, United States
- Founded
- 2014
- Employees
- 56
- Website
- admerahealth.com/
- Ownership
- Privately Held (backing)
Admera Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Admera Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Admera Health in its N-PORT filings yet. We sweep new filings monthly.